Tag:

Alere

Latest Headlines

Latest Headlines

Alere rejects Abbott's $50M breakup offer for megamerger deal

Abbott has avoided addressing rumors that its deal with point-of-care diagnostics maker Alere is on the rocks. But according to Alere, the Illinois med tech wants out.

DOJ targets Alere over international sales for point-of-care tests

Diagnostics maker Alere seemed to have closed one chapter after agreeing to sell out to Abbott last month. But some of the company's problems are coming back to haunt it as the U.S. Department of Justice (DOJ) investigates Alere's international sales practices.

UPDATED: Abbott inks $5.8B deal for Alere to expand in point-of-care diagnostics

Over the summer, Abbott said that it was keeping an eye out for potential deals, even if it didn't want one with St. Jude. Now, the company has landed on its next purchase, snatching up diagnostics outfit Alere to bulk up in point-of-care diagnostics and expand its international reach.

Diagnostics companies jump into rapidly growing market for point-of-care superbug tests

As drug-resistant superbug infections continue to rise, diagnostics companies are rolling out rapid, point-of-care devices that can quickly identify infectious bacteria and potentially cut down on the need for unnecessary antibiotics, cashing in on a growing market for the tools.

Alere revs up engine with new deals and win for quick strep test

Alere recently sold its BBI Diagnostics unit, snatched up a new diagnostics company and grabbed an FDA CLIA waiver for its quick strep test as part of its turnaround plan.

Alere revs up engine with new deals and win for quick strep test

Alere recently sold its BBI Diagnostics unit, snatched up a new diagnostics company and grabbed an FDA CLIA waiver for its quick strep test as part of its turnaround plan.

Alere keeps diagnostics ball rolling with new deals and quick strep test win

Alere recently sold off its BBI Diagnostics unit, scooped up a new diagnostics company and nabbed an FDA CLIA waiver for its quick strep test, helping the company distance itself from its troubled past.

Alere earns FDA clearance for rapid diagnostic of Strep A

Alere announced FDA clearance of its Alere i Strep A test to detect Strep A bacteria in 8 minutes or less using throat swab specimens.

Alere earns FDA clearance for rapid diagnostic of Strep A

Alere announced FDA clearance of its Alere i Strep A test to detect Strep A bacteria in 8 minutes or less using throat swab specimens.

Alere snags first FDA CLIA waiver for molecular influenza test

Alere won an FDA CLIA waiver for its molecular influenza test, giving the company a boost amid restructuring efforts and putting its diagnostic in the hands of more healthcare professionals as flu season reaches epidemic status.